Abstract 1549P
Background
The genomic profile of gastric or GEJ cancer is unclear in cases that have recurred after primary adjuvant chemotherapy. We investigated genomic alterations (GA) detected in ctDNA using a liquid biopsy test and compared the results to the those of the primary tumor.
Methods
This prospective observational study was conducted at 17 institutes from Jan 2021 to Dec 2022. Eligible patients (pts) had previously resected stage II or III gastric/GEJ cancer with recurrence after or during adjuvant chemotherapy. Whole blood was collected before chemotherapy for recurrent disease; ctDNA was analyzed using a next-generation sequencing gene panel (Guardant360). The primary endpoint was the detection rate of actionable GA with at least level 3 evidence by OncoKB for any cancer type. Secondary endpoints included a comparison of ctDNA and primary tumor GA profiles, and biomarkers relevant to clinical outcomes. A binomial test was used to determine with 90% probability that actionable GA were found in ctDNA in more than 5% of cases.
Results
Among 51 enrolled pts, 50 were available for analysis, 14% stage II and 86% stage III. The most common primary site was gastric body (56%) followed by gastric antrum (26%), and GEJ (12%). The number of metastatic sites was 1 for 76%, 2 for 18%, and 3 for 6% pts. Liquid biopsy analysis detected actionable GA in 64% [90%CI: 49.2-77.1] and actionable GA for targeted therapy in 36% pts [90%CI: 22.9-50.8, P=0.0075]:PIK3CA in 20%, ARID1A in 10%, ERBB2 in 8% (6% amplification and 2% mutation), ATM in 6%, and BRCA2, EGFR, IDH2, RAF1, and ROS1 in 2% pts each. MSI-high was detected in one patient. Comparison of primary tumor DNA and ctDNA at recurrence is ongoing.
Conclusions
Using ctDNA analysis, our study demonstrated that potentially actionable GA occur in nearly one-third of pts with recurrence after curative-intent treatment of stage II-III gastric/GEJ cancer. Genomic profiling should be strongly considered in this setting. We will compare these data with genomic analysis of primary tumor tissues.
Clinical trial identification
UMIN000043080.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Intramural Research Grants of St. Marianna University School of Medicine.
Disclosure
H. Takeda: Financial Interests, Personal, Invited Speaker: Taiho, MSD, BMS, Chugai. S. Suzuki: Financial Interests, Personal, Funding: Pfizer Japan Inc. Y. Kito: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo. A. Makiyama: Financial Interests, Personal, Invited Speaker: Eli Lilly, Taiho, Ono, Daiichi Sankyo, Bristol Myers Squibb. M. Nakamura: Financial Interests, Personal, Invited Speaker: Bayer Yakuhin, Ltd., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Bio Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Merck & Co., Inc., Servier. Y. Sunakawa: Financial Interests, Personal, Invited Speaker: Eli Lilly Japan, Bristol Myers Squibb, Chugai Pharmaceutical, Takeda, Taiho Pharmaceutical, Merck, Daiichi Sankyo, Ono Pharmaceutical; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal and Institutional, Research Grant: Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda, Otsuka Pharma, Parexel International Inc., IQVIA, Ono Pharmaceutical, CMIC Shift Zero K.K., PRA Health Sciences, Inc., Amgen; Non-Financial Interests, Project Lead: Japan Clinical Cancer Research Organization. All other authors have declared no conflicts of interest.
Resources from the same session
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21